Walter H. Moos leads SRI Biosciences, an organization with all of the resources necessary to take research programs from idea to IND® and beyond — from initial discoveries to investigational new drug applications to start human clinical trials. SRI Biosciences performs basic research on disease mechanisms, drug discovery, and full-service preclinical contract R&D.
During his career, Moos has made significant contributions to all stages of drug development, from basic research, through preclinical and clinical development, to the marketplace. Prior to joining SRI in 2005, he was Chairman and CEO of MitoKor (Migenix). Previously, he was a vice president at Chiron (Novartis) and at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert (Pfizer).
Moos has served on the boards of directors of more than a dozen organizations and has served in a number of advisory capacities for academic, government, and venture capital groups. He also has edited five books, helped to found multiple scientific journals, and has more than 150 publications and patents.
Moos received his Ph.D. from the University of California Berkeley and an AB from Harvard University. He has held adjunct faculty positions at the University of Michigan; the University of California San Francisco; and James Madison University.
View Dr. Moos' publications on PubMed.